Sterling Capital Management’s Emergent Biosolutions EBS Stock Holding History

Sterling Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.8K	Sell	1,050 -689	-40%	-$5.76K	﹤0.01%	2294
2026 Q1	$14.4K	Sell	1,739 -1,268	-42%	-$13.1K	﹤0.01%	2182
2025 Q4	$37.2K	Sell	3,007 -717	-19%	-$7.68K	﹤0.01%	1918
2025 Q3	$32.8K	Buy	3,724 +2,267	+156%	+$17.6K	﹤0.01%	1917
2025 Q2	$9.3K	Buy	+1,457	New	+$8.34K	﹤0.01%	2174
2019 Q3	$1.69M	Buy	32,282 +5,608	+21%	+$261K	0.02%	454
2019 Q2	$1.29M	Hold	26,674	–	–	0.01%	508
2019 Q1	$1.35M	Buy	26,674 +13,829	+108%	+$816K	0.01%	484
2018 Q4	$761K	Buy	+12,845	New	+$828K	0.01%	640

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Sterling Capital Management's EBS Position: Q2 2026 in Review

Sterling Capital Management reduced its Emergent Biosolutions (EBS) stake by 40% in Q2 2026, selling an estimated $5.76K and leaving 1,050 shares worth $8.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Sterling Capital Management first reported a position in EBS in Q4 2018 and has held it in 9 quarters since. The position peaked at $1.69M in Q3 2019. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Sterling Capital Management held 1,050 shares of Emergent Biosolutions worth $8.8K as of Q2 2026.
Sterling Capital Management sold 689 Emergent Biosolutions shares in Q2 2026, an estimated $5.76K.
Emergent Biosolutions made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2294 holding.
Sterling Capital Management first reported a position in Emergent Biosolutions in Q4 2018 and has held it in 9 quarters since.
Sterling Capital Management's Emergent Biosolutions position peaked at $1.69M in Q3 2019.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.